# ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
Canonical URL: https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2025-financial-resul-b7d8e0a4
Ticker: ANIP
Company: ANI Pharmaceuticals
Source: ANI Pharmaceuticals
Published: 2026-02-13 11:50 EST
## Summary

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will...

## Article Body
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:

| Date | Friday, February 27, 2026 |
| --- | --- |
| Time | 8:00 a.m. ET |
| Toll free (U.S.) | 800-274-8461 |
| Conference ID | 5230834 |
| Webcast (live and replay) | www.anipharmaceuticals.com , under the “Investors” section |

The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 12 months following the event.

About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com .

Investor Relations: Courtney Mogerley, Argot Partners T: 646-368-8014 E: ani@argotpartners.com
## Recent Company News
- 2026-07-24 10:50 EST — [ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-7-f8a7cc57) — Source: ANI Pharmaceuticals
- 2026-07-16 20:34 EST — [ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-intent-to-appeal-rulings-in-cg-oncology-matter-62a30dad) — Source: ANI Pharmaceuticals
- 2026-07-13 10:50 EST — [ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-o-658a24f6) — Source: ANI Pharmaceuticals
- 2026-05-27 10:50 EST — [ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conferenc-f9d25fa3) — Source: ANI Pharmaceuticals
- 2026-05-08 10:50 EST — [ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2026-financial-results-and-raises-2026-8805534e) — Source: ANI Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)